Biopharma Companies Explain Brexit Preparations

Gearing up for the prospect of the UK departing from the EU without a deal, biopharma companies are preparing with different precautions costing upward of $100 million per company.

Novartis on Friday offered its take on the latest preparations, raising alarms about the implications.